California's stem cell agency confronts uncertain future
By David Jensen,
Capitol Weekly
| 05. 23. 2017
C. Randal Mills, the 45-year-old CEO of California’s $3 billion stem cell research program, is a man who loves his milestones.
A private pilot, he charts his course in the air from one specific point to the next. Three years ago, Mills brought that same sort of navigation to the state stem cell agency. Miss one of the agency’s milestones, and — if you’re a stem cell scientist — you may not crash and burn, but you could lose millions of dollars in research funding from the state.
Since the agency’s inception, it has spent money at the rate of $22,000 an hour. But it has yet to finance a stem cell therapy that is available to the general public.
Mills has left an indelible stamp on the agency with his emphasis on concrete, measurable results. But he is resigning from the research program at the end of June in the midst of what some say is its “last stage.” His surprise departure to head the world’s largest bone marrow donor organization shocked many in California’s stem cell community. And...
Related Articles
By Staff, National Women's Law Center | 08.13.2025
INTRODUCTION
Baby bonuses. Motherhood medals. Fertility tracking. You may have heard of these policy proposals as solutions from the Trump administration to help encourage women to have more children.
Besides falling short of ensuring that people have what they need...
By Zusha Elinson, The Wall Street Journal | 08.12.2025
BERKELEY, Calif.—Tsvi Benson-Tilsen, a mathematician, spent seven years researching how to keep an advanced form of artificial intelligence from destroying humanity before he concluded that stopping it wasn’t possible—at least anytime soon.
Now, he’s turned his considerable brainpower to promoting...
By Cade Metz, The New York Times | 08.04.2025
Image by Mike MacKenzie / CC BY 2.0
In downtown Berkeley, an old hotel has become a temple to the pursuit of artificial intelligence and the future of humanity. Its name is Lighthaven.
Covering much of a city block, this...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...